N/A N=26 Study Evaluating the Treatment of Occipital Neuralgia
Occipital Neuralgia
Primary: A Reduction in Either Pain Frequency or Severity Associated With Occipital Neuralgia. — 2.5; 2.7 point improvement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia
Occipital Neuralgia
Primary: Change in Average Occipital Pain 6 Weeks After the Start of Treatment — 3.068; 3.738 units on a scale
Phase 3 N=58 Occipital Blocks for Acute Migraine
Chronic Migraine, Headache · Episodic Migraine
Primary: Mean Change in Pain Intensity Scores Measured by the Numeric Analog Scale (NRS) — 2.3; 1.1 score on a scale — p=0.013
Phase 4 N=70 Greater Occipital Nerve Block for Migraine Prophylaxis
Migraine Headache
Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…
Phase 4 N=60 Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain
Typical Facial Pain · Atypical Facial Pain
Primary: The Proportion of Subjects Reporting at Least 50% Overall Pain Relief — 19; 14; 10; 16 Participants — p=.196
Phase 4 N=99 Greater Occipital Nerve Block Versus Metoclopramide
Migraine
Primary: 0-10 Pain Score — 5.0; 6.1 units on a scale
N/A N=87 Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
Migraine Disorders
Primary: Change of Frequency of Headache — 5.3; 7.5 score on a scale
N/A N=120 Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
Migraine
Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale
Phase 3 N=28 Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
Migraine
Primary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants
N/A N=6 Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI
Facial Neuropathy
Primary: Blood Oxygenation Level-dependent (BOLD) Changes in Neural Pain Circuitry Following Treatment With Lamotrigine During Experimentally Induced Pain States — -2.9294…
N/A N=187 The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Acute Migraine
Primary: Proportion of Subjects Reporting Reduction of Migraine Headache Pain at 2 Hours From Treatment Initiation — 30; 22 Participants — p=0.018
N/A N=9 Transcranial Magnetic Stimulation for Facial Pain
Trigeminal Nerve Injuries · Post-herpetic Neuralgia · Facial Pain
Primary: Visual Analogue Scale (VAS) — 5.4 score on a scale
N/A N=90 Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches
Medication Overuse Headache · Chronic Migraine, Headache
Primary: Visual Analog Scale — 8.3; 8.4; 5.3; 5.3 units on a scale
Phase 4 N=62 Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine
Headache · Pregnancy Related · Occipital Nerve Block
Primary: Number of Participants With Response to Occipital Nerve Block in Pregnancy — 20; 16 Participants — p=0.30
Phase 2 N=50 External Trigeminal Nerve Stimulation for Epilepsy
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
Phase 4 N=25 Erenumab for Idiosyncratic Facial Pain
Facial Pain · Rhinosinusitis
Primary: Change in Mean Number of Days Per Month With Significant Mid-facial Pain or Pressure — -6.0; -5.8 days per month — p=0.96
Phase 2 N=27 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
N/A N=40 Citicoline in Non-Arteritic Ischemic Optic Neuropathy
Non-arteritic Ischemic Optic Neuropathy
Primary: Change From Baseline in Visual Acuity at 9 Month — -0.0574; 0.0535 LogMAR
Phase 2 N=133 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
Nerve Pain
Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. — -1.53; -1.54; -1.44 Scores on a scale
N/A N=20 Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia
Trigeminal Neuralgia
Primary: Average Number of Pain Attacks — 3.3533; 3.1807 Pain attacks
N/A N=3 Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches
Migraine Headache
Primary: Migraine Relief at 2 Hours Post Stimulation
N/A N=112 Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
Intractable Chronic Migraine
Primary: Adverse Events (First 12 Weeks) — 17; 27; 5; 1 events
Phase 4 N=20 Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Trigeminal Neuralgia · Glossopharyngeal Neuralgia
Primary: Change in Pain Score — -0.6224; -1.005; -0.8102; -1.079 score on a scale
Phase 2 N=37 Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy
Trigeminal Neuralgia
Primary: Time to Return to Baseline Pain After Injection. — 8; 5 hours — p=0.374
Phase 1 N=2 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart
N/A N=20 Vertebral Artery and Cerebral Hemodynamics After Various Head Positions & Manipulation in Patients With Neck Pain
Vertebral Artery Dissection · Cerebrovascular Accident · Stroke
Primary: Changes in Blood Flow Through the Vertebral Artery and Posterior Cerebral and Cerebellar Circulation — 15.5; 15.1; 14.7 cm/s
Phase 2 N=10 Tailored Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain
Neck Pain
Primary: Occiflex Device Safety — 26 Number of adverse effects
Phase 2 N=165 Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
Tension-Type Headache
Primary: Number of Subjects Pain Free — 21; 20; 21; 19 Participants
Phase 2 N=117 Traumatic Optic Neuropathy Treatment Trial (TONTT)
Traumatic Optic Neuropathy
Primary: Number of Participants With Change/Improvement Visual Acuity From the Beseline — 28; 3; 5 Participants
Phase 2 N=22 Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Non-arteritic Ischemic Optic Neuropathy · Optic Nerve Injuries
Primary: Mean Increase From Baseline in ETDRS Letters Read at 26 Weeks and Off-drug Follow-up Visit — 15; 7; 9; 6 EDTRS Letters